Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Country/Region as subject
Language
Publication year range
1.
Nutrients ; 13(11)2021 Nov 19.
Article in English | MEDLINE | ID: mdl-34836393

ABSTRACT

We analyzed the effectiveness of two nutritional interventions alone and together, EVOO and the DieTBra, on the inflammatory profile of severely obese individuals. This study was an RCT with 149 individuals aged from 18 to 65 years, with a body mass index ≥ 35 kg/m2, randomized into three intervention groups: (1) 52 mL/day of EVOO (n = 50); (2) DieTBra (n = 49); and (3) DieTBra plus 52 mL/day of EVOO (DieTBra + EVOO, n = 50). The primary outcomes we measured were the-neutrophil-to-lymphocyte ratio (NLR) and the secondary outcomes we measured were the lymphocyte-to-monocyte ratio (LMR); leukocytes; and C reactive protein (CRP). After 12 weeks of intervention, DieTBra + EVOO significantly reduced the total leucocytes (p = 0.037) and LMR (p = 0.008). No statistically significant differences were found for the NLR in neither the intra-group and inter-group analyses, although a slight reduction was found in the DieTBra group (-0.22 ± 1.87). We observed reductions in the total leukocytes and LMR in the three groups, though without statistical difference between groups. In conclusion, nutritional intervention with DietBra + EVOO promotes a significant reduction in inflammatory biomarkers, namely leukocytes and LMR. CRP was reduced in EVOO and DieTBra groups and NLR reduced in the DieTBra group. This study was registered at ClinicalTrials.gov under NCT02463435.


Subject(s)
Diet, Healthy/methods , Inflammation Mediators/blood , Obesity, Morbid/blood , Obesity, Morbid/diet therapy , Olive Oil/administration & dosage , Adolescent , Adult , Aged , Biomarkers/blood , Body Mass Index , Brazil , C-Reactive Protein/analysis , Diet, Healthy/ethnology , Female , Humans , Inflammation , Leukocytes , Lymphocytes , Male , Middle Aged , Monocytes , Neutrophils , Treatment Outcome , Young Adult
2.
Nutrients ; 12(10)2020 Sep 28.
Article in English | MEDLINE | ID: mdl-32998416

ABSTRACT

Antiretroviral therapy (ART) increases the risk of cardiometabolic diseases in people living with HIV/AIDS (PLWHA). However, there is a lack of evidence regarding the effectiveness of a nutritional intervention on several cardiometabolic parameters in this population. Therefore, this study aimed to evaluate the effectiveness of two nutritional interventions on several cardiometabolic parameters in PLWHA treated with ART. A parallel randomized clinical trial was performed with PLWHA treated with ART. The participants (n = 88) were divided into two intervention groups: (1) nutritional counseling (n = 44) and (2) individualized dietary prescription (n = 44). The follow-up period was 30 weeks. A reduction in low-density lipoprotein (LDL) was the primary outcome. Secondary outcome variables were reductions in total cholesterol (TC), triglycerides (TG), fasting plasma glucose (FPG), systolic and diastolic blood pressures (SBP and DBP, respectively), waist circumference (WC), body mass index (BMI), and increases in high-density lipoproteins (HDL). A multiple linear regression was used to analyze the effectiveness of the interventions, adjusted for sociodemographic, lifestyle, and clinical characteristics. Sixty-two PLWHA completed the trial (nutritional counseling, n = 32; individualized dietary prescription, n = 30). At follow-up, we observed in the nutritional counseling group significant reductions in SBP (p = 0.036) and DBP (p = 0.001). Significant reductions in FPG (p = 0.008) and DBP (p = 0.023) were found in the individualized dietary prescription group. In the fully adjusted models, significant reductions in LDL, SBP, DBP, and BMI were found in the individualized dietary prescription group. In conclusion, the two investigated nutritional interventions were effective in reducing some cardiometabolic risk factors in PLWHA. However, after adjustments for covariates, the individualized dietary prescription showed significant reductions in the primary outcome and, also, in more cardiometabolic risk factors than the nutritional counseling.


Subject(s)
Counseling/methods , Dyslipidemias/therapy , HIV Infections/therapy , HIV , Nutrition Therapy/methods , Adult , Anti-Retroviral Agents/therapeutic use , Blood Glucose/analysis , Blood Pressure , Body Mass Index , Cardiometabolic Risk Factors , Cholesterol/blood , Combined Modality Therapy , Dyslipidemias/physiopathology , Dyslipidemias/virology , Fasting/blood , Female , HIV Infections/complications , HIV Infections/physiopathology , Humans , Linear Models , Lipoproteins, HDL/blood , Lipoproteins, LDL/blood , Male , Middle Aged , Treatment Outcome , Triglycerides/blood , Waist Circumference
3.
Nutrients ; 12(2)2020 Feb 04.
Article in English | MEDLINE | ID: mdl-32032997

ABSTRACT

Dietary interventions can stabilize and/or reverse bone mass loss. However, there are no reports on its effects on bone mineral density (BMD) in severely obese people, despite the vulnerability of this group to bone loss. We examine the effect of extra virgin olive oil supplementation and the traditional Brazilian diet (DieTBra) on BMD and levels of calcium, vitamin D, and parathyroid hormone (PTH) in severely obese adults. A randomized controlled trial followed-up with severely obese adults (n = 111, with mean body mass index 43.6 kg/m2 ± 4.5 kg/m2) for 12 weeks. Study participants received either olive oil (52 mL/day), DieTBra, or olive oil + DieTBra (52 mL/day + DieTBra). BMD was assessed by total spine and hip dual-energy X-ray absorptiometry. After interventions, BMD means for total spine (p = 0.016) and total hip (p = 0.029) were higher in the DieTBra group than in the olive oil + DieTBra group. Final mean calcium levels were higher in the olive oil group compared to the olive oil + DieTBra group (p = 0.026). Findings suggest that DieTBra and extra virgin olive oil have positive effects on bone health in severely obese adults. The major study was registered at ClinicalTrials.gov (NCT02463435).


Subject(s)
Bone Density , Diet/methods , Dietary Supplements , Obesity, Morbid/diet therapy , Olive Oil/administration & dosage , Absorptiometry, Photon , Adolescent , Adult , Bone Diseases, Metabolic/etiology , Bone Diseases, Metabolic/prevention & control , Brazil , Calcium/blood , Diet/ethnology , Female , Humans , Male , Obesity, Morbid/complications , Obesity, Morbid/physiopathology , Parathyroid Hormone/blood , Pelvic Bones/diagnostic imaging , Pelvic Bones/physiopathology , Spine/diagnostic imaging , Spine/physiopathology , Vitamin D/blood , Young Adult
4.
Clin Nutr ; 36(3): 680-685, 2017 06.
Article in English | MEDLINE | ID: mdl-27395330

ABSTRACT

BACKGROUND & AIMS: Gastrointestinal symptoms are among the most frequent reported complaints by people living with HIV and AIDS (PLWHA). Treatments that aim to attenuate these symptoms are important to avoid low adherence to antiretroviral therapy and to improve the quality of life. This study aimed to evaluate the effectiveness of nutritional treatment and synbiotic use in PLWHA on reducing gastrointestinal symptoms. METHODS: A randomized clinical trial nested to an outpatient cohort was conducted to evaluate the effectiveness of two treatments for gastrointestinal symptoms reduction in adult patients with antiretroviral therapy presenting at least one gastrointestinal symptom: 1) nutritional treatment + placebo (6 g maltodextrin) and 2) nutritional treatment + synbiotic (Lactobacillus and Bifidobacterium strains + 6 g fructooligosaccharides). Placebo and synbiotic were consumed twice a day during six months. The primary outcome variable was percentage reduction in the incidence of diarrhea, and secondary outcomes the decrease in the incidence of nausea and/or vomiting, dyspepsia, heartburn, constipation, flatulence, and the presence of three or more gastrointestinal symptoms. RESULTS: Out of 283 patients evaluated for eligibility, 64 met inclusion criteria to enter in this study with 1:1 allocation ratio. Both analyzed groups were homogeneous regarding sociodemographic, clinical and lifestyle variables at baseline. In the intergroup analysis, no difference was found between groups except for heartburn, which had a higher reduction in the placebo group (0.01). Regarding the intragroup analysis, in the placebo group a significant decrease in diarrhea (p = 0.02) and heartburn (p < 0.01) were observed while there was a significant reduction for nausea e/or vomit (p = 0.01), dyspepsia (p = 0.10), diarrhea (p = 0.01) and constipation (p = 0.08) in the synbiotic group. CONCLUSIONS: Diarrhea decreased in both groups, but no statistical difference between treatments was observed. The use of synbiotic appeared to reduce a greater number of symptoms although there were no statistical differences in the intergroup analysis. This clinical trial was registered at ClinicalTrials.gov (NCT02180035).


Subject(s)
Diet , Gastrointestinal Diseases/prevention & control , HIV Infections/therapy , Synbiotics/administration & dosage , Adult , Bifidobacterium , Double-Blind Method , Female , Humans , Lactobacillus , Male , Middle Aged , Oligosaccharides/administration & dosage , Quality of Life , Socioeconomic Factors , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL